Powered by Infomedica Infomedica Conference Coverage* of 26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13,

Slides:



Advertisements
Similar presentations
The ENCORE Study Cardiovascular Benefits Associated With the DASH Diet Alone and in Combination with Exercise and Weight Reduction in Men and Women with.
Advertisements

JNC 8 Guidelines….
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Valsartan Antihypertensive Long-Term Use Evaluation Results
Overcoming the challenge of blood pressure control in prediabetic and diabetic patients: PICASSO T2D Study Efficacy and tolerability of fixed dose combination.
Effectiveness of interactive web-based lifestyle program on prevention of cardiovascular diseases risk factors in patient with metabolic syndrome: a randomized.
BHS Guidelines for the management of hypertension BHS IV, 2004 and Update of the NICE Hypertension Guideline, 2006 Guidelines for management of hypertension:
Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang,
The concept of Diabetes & CV risk: A lifetime risk challenge
Uncontrolled Hypertension, Systolic and Diastolic Blood Pressure and Development of Symptomatic Peripheral Arterial Disease in the Women’s Health Study.
HOME AND AMBULATORY BLOOD PRESSURE MONITORING
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
DECREASING SLEEP-TIME BLOOD PRESSURE DETERMINED BY AMBULATORY MONITORING REDUCES CARDIOVASCULAR RISK Ramón C. Hermida, PhD; Diana E. Ayala, MD, MPH, PhD;
1 The Study of Trandolapril- verapamil And insulin Resistance STAR determined whether glycaemic control was maintained to a greater degree by an RAS inhibitor/non-DHP.
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
Morbidity and Mortality in Contemporary CAD Patients With Hypertension Treated With Either a Verapamil/Trandolapril or Beta-Blocker/Diuretic Strategy (INVEST):
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
To assess the prognostic value of variability in home-measured blood pressure (BP) and heart rate (HR) in a general population. Objective: Methods: BP.
Monocyte damaged endothelium macrophage foam cell lipid thrombocytes plaque oxidative stress smooth muscle cells 4 5 Gaviraghi et al., 1998 Lacidipine:
HvC Comparative Effectiveness Project Groups 5 and 6
Pharmacist-Physician Collaborative Medication Therapy Management Services (MTMS) PI: Jan Hirsch, RPh, PhD Carol M. Mangione, MD, MSPH Barbara A. Levey.
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA.
A Controlled Trial of Renal Denervation for Resistant Hypertension
Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes Featured.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
Canagliflozin Cardiovascular Safety. 2 Potential CV protection pathways of SGLT2i Diab Vasc Dis Res Mar;12(2):
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Renal Denervation on 24-Hour Ambulatory.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Renal Denervation in Moderate Treatment-Resistant.
Journal Club February 7, 2014 Sadie T. Velásquez, MD.
Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm VBWG.
Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Exercise and Weight Loss Reduce Blood Pressure in.
Powered by Infomedica Infomedica Conference Coverage* of 26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13,
Category Sex Systolic BP (mmHg) Men (n=58) Women (n=106) P value
Antonio Coca, MD, PhD, FRCP, FESC
Dr John Cox Diabetes in Primary Care Conference Cork
Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)
An analysis of 22,672 patients from the CLARIFY registry
ALICE-PROTECT Study Yields Online Risk Prediction Tool in Diabetic Nephropathy From ESH 2016 | LB 1: Jean-Pierre Fauvel, MD CHU Lyon, Hôpital E Herriot,
Nephrology Journal Club The SPRINT Trial Parker Gregg
From ESH 2016 | POS 4C: A. Power, MD
Hypertension November 2016
Hypertension in the Post SPRINT era
*Imperial College London
From ESH 2016 | POS 3C: Chiara Lorenzi, MD
FDA Pathway to Approval: Clinical Requirements for Renal Denervation
Eoin O’Brien, DSc, MD, Eamon Dolan, MD, FRCPI  Clinical Therapeutics 
Daily Stress, Coping, and Nocturnal Blood Pressure Dipping
From ESH 2016 | POS 7D: Jan Rosa, MD
Health and Human Services National Heart, Lung, and Blood Institute
Vanguard Phase Results for the Blood Pressure Component
From ESH 2016 | POS 3C: Luiz Aparecido Bortolotto, MD, PhD
BEAUTY Trial: Hypertension Control Not Improved with Hemodynamic Monitoring From ESH 2016 | LB 3: Pierre Boutouyrie, MD, PhD INSERM, Université Paris Descartes,
Neal B, et al. Diabetes Care 2015;38:403–411
Aliskiren and Valsartan for Antihypertensive Therapy Trial
United States Preventive Services Task Force: Recommendations for ABPM
PS Sever, PM Rothwell, SC Howard, JE Dobson, B Dahlöf,
Improving Chronic Care Management
Systolic Blood Pressure Intervention Trial (SPRINT)
Progress and Promise in RAAS Blockade
The Hypertension in the Very Elderly Trial (HYVET)
Determinants of new onset diabetes among hypertensive patients randomised in the ASCOT-BPLA Trial Dr Ajay K Gupta International Centre for Circulatory.
These slides highlight a report based on original presentations at the 24th Meeting of the French Society of Arterial Hypertension (SFHTA) in Paris, France,
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.
Hypertension November 2016
VK2809 in NAFLD: a phase 2 study
Effects of placebo or carvedilol CR on 24-hour mean systolic blood pressure and diastolic blood pressure obtained by ambulatory monitoring in hypertensive.
Presentation transcript:

Powered by Infomedica Infomedica Conference Coverage* of 26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13, 2016 * Infomedica is an independent medical education provider that produces medical information to healthcare professionals through conference coverage and online educational programs and activities. 26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13, 2016 HARMONY: Similar Results with Morning and Evening Dosing of Antihypertensive Therapy From ESH 2016 | LB 1: Neil R. Poulter, MD Imperial College London, United Kingdom

26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13, 2016 Powered by Infomedica Overview  Morning or evening administration of antihypertensive medication had no effect on blood pressure levels measured by 24-hour ambulatory blood pressure monitoring (ABPM) or on quality of life in the HARMONY study  Optimal timing of administering antihypertensive medications to reduce major adverse cardiovascular events (MACE) is subject of research  Some nighttime dosing has been suggested to be beneficial by some research

26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13, 2016 Powered by Infomedica HARMONY Design  Women and men aged years with well- controlled blood pressure (≤150 mmHg systolic and ≤90 mmHg diastolic) for ≥3 months on ≥1 antihypertensive medication were randomized to taking their medication in the morning (between 6 and 11 am) or in the evening (between 6 and 11 pm); at 12 weeks, without a washout period, patients were crossed over to the other time period  All patients took their usual antihypertensive therapy  Primary endpoint: mean 24-hour systolic blood pressure (SBP) measured by ABPM

26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13, 2016 Powered by Infomedica Overview: Baseline Characteristics in Patients in HARMONY VariableEvening/MorningMorning/Evening N 5251 Age, mean (SD) 61.8 (9.7)61.8 (11.0) Female, N (%) 21 (40)24 (47) BMI, mean (SD) 29.1 (5.6)29.1 (4.7) Heart rate, mean (SD) 72.8 (10.3)72.7 (9.6) Systolic BP, mean (SD) (8.7)129.0 (8.8) Diastolic BP, mean (SD) 76.6 (6.1)76.3 (6.2) Current smoker, N (%) 4 (8)8 (16) Alcohol units per week, mean (SD) 16.7 (17.2)11.8 (11.9) Fasting plasma glucose, mean (SD) 5.6 (0.9)5.5 (1.0) Non-HDL cholesterol, mean (SD) 3.4 (1.0)3.5 (1.0) BP, blood pressure; DBP, diastolic blood pressure; QOL, quality of life; SBP, systolic blood pressure.

26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13, 2016 Powered by Infomedica Overview: Achieved Blood Pressures by Doing Time for Primary and Secondary Endpoints Outcome mmHg (N=95) Baseline Drug taken Observed difference (Evening - Morning) Adjusted difference (95% CI) MorningEvening 24h Systolic BP (-3.20, 3.42) 24h Diastolic BP (-1.38, 2.91) Day time SBP (-2.82, 3.89) Day time DBP (-0.96, 3.56) Night time SBP (-5.38, 2.15) Night time DBP (-2.81, 2.17) Clinic SBP (-2.91, 3.69) Clinic DBP (-2.03, 2.32) QOL score (-3.12, 2.89) BP, blood pressure; DBP, diastolic blood pressure; QOL, quality of life; SBP, systolic blood pressure.

26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13, 2016 Powered by Infomedica Results  No difference observed for the primary endpoint or any prespecified secondary endpoints in relation to timing of therapy  Largest between-group difference seen for nighttime systolic blood pressure, although not significant, could be important at population level in relation to reducing CV events  No impact on quality of life in relation to timing of therapy

26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13, 2016 Powered by Infomedica Results  Definitive evidence on a benefit of nighttime doing for MACE prevention will come from the ongoing Treatment in Morning versus Evening (TIME) trial with 10,200 patients followed for 5 years

Powered by Infomedica Infomedica Conference Coverage* of 26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13, 2016 * Infomedica is an independent medical education provider that produces medical information to healthcare professionals through conference coverage and online educational programs and activities. 26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13, 2016 HARMONY: Similar Results with Morning and Evening Dosing of Antihypertensive Therapy From ESH 2016 | LB 1: Neil R. Poulter, MD Imperial College London, United Kingdom